Sublocade (buprenorphine once-monthly depot) / Indivior 
Welcome,         Profile    Billing    Logout  
 0 Diseases   6 Trials   6 Trials   205 News 


«12345»
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Trial completion date, Trial initiation date, Trial primary completion date:  Monthly Injectable BUP for MA Use Disorder (MURB) Trial (clinicaltrials.gov) -  Nov 9, 2022   
    P2,  N=246, Not yet recruiting, 
    Trial completion date: Jan 2025 --> Apr 2025 | Initiation date: Oct 2022 --> Jan 2023 | Trial primary completion date: Oct 2024 --> Jan 2025
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Trial completion date, Trial primary completion date:  Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder (clinicaltrials.gov) -  Sep 30, 2022   
    P2,  N=40, Recruiting, 
    Trial completion date: Jan 2025 --> Apr 2025 | Initiation date: Oct 2022 --> Jan 2023 | Trial primary completion date: Oct 2024 --> Jan 2025 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Trial completion date, Trial primary completion date:  Monthly Injectable BUP for MA Use Disorder (MURB) Trial (clinicaltrials.gov) -  Sep 19, 2022   
    P2,  N=246, Not yet recruiting, 
    HSSP support can provide significant benefit to patients and the health system through coordinating ER-buprenorphine dispensing and delivery. Trial completion date: Jun 2024 --> Jan 2025 | Trial primary completion date: May 2024 --> Oct 2024
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Review, Journal:  Buprenorphine and its formulations: a comprehensive review. (Pubmed Central) -  Aug 25, 2022   
    Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Trial completion date, Trial primary completion date:  BOPAT: Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections (clinicaltrials.gov) -  Jun 27, 2022   
    P2,  N=90, Recruiting, 
    In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations. Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Aug 2024
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films (clinicaltrials.gov) -  Jun 6, 2022   
    P2,  N=0, Withdrawn, 
    Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Aug 2024 N=30 --> 0 | Trial completion date: Dec 2021 --> Dec 2022 | Suspended --> Withdrawn | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Journal:  The impacts of PLGA/PEG triblock copolymers with variable molecular weights on sustained release of buprenorphine. (Pubmed Central) -  Apr 13, 2022   
    These analyses provide guidance to physicians for transitioning patients stable on transmucosal buprenorphine to Sublocade and demonstrate the importance of initiating Sublocade treatment with one or 2 monthly doses of 300 mg. These results indicated that ISFC 1500 wasbiocompatible and delivered suitable early initial burst reactions compared with ISFC 3000 and 4000 and might be a good candidate for preparing sustained-release formulation of BP.
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Long-Term Treatment Benefit of BUP-XR for Patients Struggling to Abstain from Opioids (Great Hall Foyer, Third Floor) -  Apr 8, 2022 - Abstract #ASAM2022ASAM_277;    
    P3
    Introduction BUP-XR (SUBLOCADE®) is an extended-release monthly depot formulation of buprenorphine for the treatment of opioid use disorder (OUD)...The combined efficacy and safety profiles support clinical benefit for long-term treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT02357901 (Study 1), NCT02510014 (Study 2), NCT02896296 (Study 3)
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Enrollment closed, Enrollment change:  EXPO: Extended-release Pharmacotherapy for Opioid Use Disorder (clinicaltrials.gov) -  Feb 21, 2022   
    P3,  N=342, Active, not recruiting, 
    Trial Registration: ClinicalTrials.gov Identifier: NCT02357901 (Study 1), NCT02510014 (Study 2), NCT02896296 (Study 3) Recruiting --> Active, not recruiting | N=604 --> 342
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Enrollment change:  VOTIVE: Virginia Opioid Overdose Treatment InitiatVE (clinicaltrials.gov) -  Dec 16, 2021   
    P3,  N=20, Terminated, 
    Trial registration Registered at Clinicaltrials.gov NCT04375033. N=37 --> 20
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Review, Journal:  Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations. (Pubmed Central) -  Oct 12, 2021   
    Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly application; (2) RBP-6000 (Sublocade™) as a monthly depot formulation; and (3) A six-month buprenorphine implant [Probuphine™]. The pharmacology, clinical efficacy and prospects of these medications are discussed.
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Journal:  Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update. (Pubmed Central) -  Sep 23, 2021   
    Three novel long-acting buprenorphine formulations have been approved or will be available soon: for subcutaneous weekly and monthly application, the depot formulations CAM 2038 (Buvidal), the monthly depot formulation RBP-6000 (Sublocade™), and a 6-month buprenorphine implant (Probuphine™). Clinical data available so far on the efficacy of these 3 medications are given, and possible clinical implications are discussed.
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Clinical, Journal:  Prolonged-release buprenorphine formulations: Perspectives for clinical practice. (Pubmed Central) -  Sep 19, 2021   
    Buvidal®/Brixadi® is a one-week- or one-month-long depot formulation with multiple dosages, which can be used in initiation or in switched from sublingual formulations. While opioid users report some concerns with a risk of coercive use of long-acting forms of buprenorphine, both users and professionals deem that these new specialties could be particularly appreciated in stabilized patients bothered with the daily intake of the treatments, or specific situations at risk of treatment dropout (e.g., following hospital discharge or prison release).
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Retrospective data, Journal, Real-world evidence:  Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series. (Pubmed Central) -  Aug 7, 2021   
    While opioid users report some concerns with a risk of coercive use of long-acting forms of buprenorphine, both users and professionals deem that these new specialties could be particularly appreciated in stabilized patients bothered with the daily intake of the treatments, or specific situations at risk of treatment dropout (e.g., following hospital discharge or prison release). This real-world evaluation of XR-BUP in a low-threshold clinic found that treatment was feasible, well tolerated, and outcomes were good, with most individuals choosing to continue treatment and a majority with no evidence of ongoing opioid use or precipitated withdrawal.
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Trial completion date, Trial primary completion date:  BOPAT: Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections (clinicaltrials.gov) -  Jul 20, 2021   
    P2,  N=90, Recruiting, 
    This real-world evaluation of XR-BUP in a low-threshold clinic found that treatment was feasible, well tolerated, and outcomes were good, with most individuals choosing to continue treatment and a majority with no evidence of ongoing opioid use or precipitated withdrawal. Trial completion date: Sep 2024 --> May 2024 | Trial primary completion date: Sep 2024 --> Feb 2024
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    [VIRTUAL] A ‘Light Touch’ Long-acting Injectable Buprenorphine Clinic for the COVID-19 Pandemic (Tamborine Gallery) -  Jul 17, 2021 - Abstract #ANZAC2021ANZAC_41;    
    The clinic allowed for rapid access to opioid agonist therapy and improved social distancing at a time of considerable community anxiety. The clinic attracted a significant subgroup that were not treatment experienced and who used prescription opioids rather than heroin alone.
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    [VIRTUAL] Initiating Monthly Buprenorphine Injection After Single Dose of Sublingual Buprenorphine () -  Jun 28, 2021 - Abstract #CPDD2021CPDD_592;    
    Knowledge generated from this work will inform the development of a larger clinical trial evaluating XR-BUP in a Canadian setting. Initiating Sublocade 300 mg following a single 4 mg dose of Suboxone demonstrated a safety profile similar to that observed with Sublocade induction per current labelling.1
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    [VIRTUAL] Depot Buprenorphine XL (Sublocade) Treatment Registry London, Canada () -  Jun 28, 2021 - Abstract #CPDD2021CPDD_111;    
    This coincides to the attainment of steady state plasma Buprenorphine levels, which occurs after 5-6 Sublocade doses. Although this is not proof of a causal relationship, this is a hypothesis to consider and suggests a basis for further research.
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  VOTIVE: Virginia Opioid Overdose Treatment InitiatVE (clinicaltrials.gov) -  Apr 22, 2021   
    P3,  N=37, Terminated, 
    N=150 --> 37 | Trial completion date: Dec 2021 --> Feb 2021 | Suspended --> Terminated | Trial primary completion date: Dec 2021 --> Feb 2021; Due to a financial business decision by the company supporting the research study (Indivior). The decision was not due to adverse events, safety reasons, or scientific reasons, but was a business decision.
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    [VIRTUAL] BUDGET IMPACT ANALYSIS OF WEEKLY AND MONTHLY SUBCUTANEOUS BUPRENORPHINE DEPOT (CAM2038) IN U.S. HEALTH PLANS () -  Apr 11, 2021 - Abstract #AMCP2021AMCP_88;    
    Treatment comparators included Suboxone® (buprenorphine/ naloxone sublingual film), generic buprenorphine/naloxone sublingual film and tablets, Vivitrol® (naltrexone injection), and Sublocade™ (buprenorphine injection). The introduction of CAM2038 as an OUD treatment resulted in a net overall savings in private and Medicaid payer costs; increased drug and administration costs were offset by reductions in all-cause medical costs.
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Enrollment open:  Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults (clinicaltrials.gov) -  Apr 1, 2021   
    P4,  N=301, Recruiting, 
    The introduction of CAM2038 as an OUD treatment resulted in a net overall savings in private and Medicaid payer costs; increased drug and administration costs were offset by reductions in all-cause medical costs. Not yet recruiting --> Recruiting